{"title":"Switch from antipsychotic polypharmacy to monotherapy reduces side effects","authors":"","doi":"10.1002/pu.31250","DOIUrl":null,"url":null,"abstract":"<p>Inpatients with schizophrenia who switched from antipsychotic polypharmacy to monotherapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open-label trial has found. The vast majority of patients in the study's switch group stopped taking a first-generation antipsychotic and continued on their second-generation drug. Study results were published online Sept. 16, 2024, in <i>Schizophrenia Research</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31250","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Inpatients with schizophrenia who switched from antipsychotic polypharmacy to monotherapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open-label trial has found. The vast majority of patients in the study's switch group stopped taking a first-generation antipsychotic and continued on their second-generation drug. Study results were published online Sept. 16, 2024, in Schizophrenia Research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
